AFM
SEEL

Anson Funds Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Anson Funds Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed -$263K – 84
2016
Q4 		$263K Sell
2
-2
-50% -$468K 0.08% 66
2016
Q3 		$1.72M Buy
+4
New +$1.6M 0.37% 32

Other funds holding SEEL

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Anson Funds Management's SEEL Position: Q1 2017 in Review

Anson Funds Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2017, closing a stake of 2 shares — an estimated $263K sold.

Anson Funds Management first reported a position in SEEL in Q3 2016 and held it in 2 quarters. The position peaked at $1.72M in Q3 2016. 2 funds tracked by Wall St. Rank hold SEEL as of Q1 2017.

  • Anson Funds Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 2 Seelos Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $263K.
  • Anson Funds Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2016 and held it in 2 quarters.
  • Anson Funds Management's Seelos Therapeutics, Inc. Common Stock position peaked at $1.72M in Q3 2016.
  • 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.